<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04242953</url>
  </required_header>
  <id_info>
    <org_study_id>SCO-120-19-18</org_study_id>
    <nct_id>NCT04242953</nct_id>
  </id_info>
  <brief_title>Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Postmenopausal Female Volunteers</brief_title>
  <official_title>A Phase 1 Randomized, Double Blind, Placebo Controlled Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120, in Healthy Postmenopausal Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharma Advanced Research Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharma Advanced Research Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 Randomized, Double blind and Placebo controlled Study to Determine Safety,
      Tolerability and Pharmacokinetics, of SCO-120 in healthy postmenopausal female volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of subjects with treatment emergent adverse events</measure>
    <time_frame>Day 14 after single dose administration in each cohort</time_frame>
    <description>safety and tolerability profile of SCO-120</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration</measure>
    <time_frame>Day 14 after single dose administration in each cohort</time_frame>
    <description>Plasma Pharmacokinetic parameters of SCO-120</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to maximum observed plasma concentration</measure>
    <time_frame>Day 14 after single dose administration in each cohort</time_frame>
    <description>Plasma Pharmacokinetic parameters of SCO-120</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>terminal rate constant</measure>
    <time_frame>Day 14 after single dose administration in each cohort</time_frame>
    <description>Plasma Pharmacokinetic parameters of SCO-120</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>terminal half-life</measure>
    <time_frame>Day 14 after single dose administration in each cohort</time_frame>
    <description>Plasma Pharmacokinetic parameters of SCO-120</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCO-120</intervention_name>
    <description>single oral administration</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>single oral administration</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing and able to give written, signed and dated informed consent (or by subject's
             legally acceptable representative/impartial witness when applicable) and is available
             for the entire study

          2. Willing and able to comply with the scheduled visits, treatment plan, laboratory
             testing, study procedures, and restrictions, and be accessible for follow-up visits

          3. Assessed as healthy based on no clinically significant abnormality identified on
             medical history, physical examination, vital signs, electrocardiogram, and clinical
             laboratory screening tests

          4. Age &gt; 18 years

          5. Weight over 50 kg and with a body mass index of 18.0 to 33.0 kg/m2 (inclusive)

          6. Female who are naturally postmenopausal for at least 12 consecutive months with a
             follicle-stimulating hormone level of â‰¥ 40 mIU/mL at screening.

        Exclusion Criteria:

          1. Any major surgery, as determined by the Investigator, within 4 weeks of IMP
             administration

          2. Inability to swallow oral medication

          3. Inability to undergo venipuncture and/or tolerate venous access

          4. Female on Hormone Replacement Therapy, or having been on the same in the past 6 months

          5. History of abnormal vaginal bleeding and/ or uterine malignancy

          6. Positive exclusion tests: human immunodeficiency virus (HIV), hepatitis B surface
             antigen, or hepatitis C virus

          7. Known and/ or suspected history of significant drug abuse as judged by the
             Investigator.

          8. Received another investigational agent within 30 days (or for investigational agents
             with long half-life a washout of 5 half-lives will be required) prior to IMP
             administration or intake of an investigational drug during the course of this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy postmenopausal female volunteers</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sun Pharma Advanced Research Company Limited</last_name>
    <phone>+1 (609) 720-5333</phone>
    <email>clinical.trials@sparcmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BioPharma Services USA Inc.</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Artan Markollari</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>BioPharma Services Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>ON M9L 3A2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Esmat Dessouki</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Colombia</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 12, 2020</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

